Nishimura Mika
CIK: 0001848327
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 30, 2026
Accuray (ARAY) noted among health‑care stocks moving in recent sessions. Accuray appeared in several recent lists of health‑care stocks showing price movement in pre‑market, after‑market and intraday sessions. The activity comes as the stock trades near its $0.25 support level with an RSI around 58, suggesting modest momentum. Analysts have an average target of $0.35, above the current price.
Transaction History
| SIBN | ▲ Buy | Grant | 10,957 | $0 | 6/4/2026 | View on chart |
| SIBN | ▼ Sell | Open Market | 4,100 | $57K | 3/12/2026 | View on chart |
| ARAY | ▲ Buy | Option Exercise | 56,603 | $0 | 11/21/2025 | View on chart |
| SIBN | ▲ Buy | Grant | 8,675 | $0 | 6/5/2025 | View on chart |
| SIBN | ▲ Buy | Grant | 8,791 | $0 | 6/26/2024 | View on chart |
| SIBN | ▼ Sell | Open Market | 2,500 | $41K | 3/13/2024 | View on chart |
| ARAY | ▲ Buy | Grant | 56,603 | $0 | 11/30/2023 | View on chart |
| SIBN | ▲ Buy | Grant | 4,866 | $0 | 6/9/2023 | View on chart |
| ARAY | ▲ Buy | Grant | 59,055 | $0 | 11/30/2022 | View on chart |
| SIBN | ▲ Buy | Grant | 8,324 | $0 | 6/16/2022 | View on chart |
| ARAY | ▲ Buy | Grant | 31,185 | $150K | 11/30/2021 | View on chart |
| ARAY | ▲ Buy | Grant | 9,213 | $37K | 8/31/2021 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 16, 2026
Truist Securities raises SI-BONE price target to $25
Truist Securities kept its existing rating on SI‑BONE and lifted its price target to $25. The new target sits near the midpoint of the nine‑analyst consensus range of $20 to $32, and slightly above the current 52‑week high of $21.89. This adjustment suggests the firm sees further upside potential for the company.
Truist Securities raises SI-BONE price target to $25. Truist Securities kept its existing rating on SI‑BONE and lifted its price target to $25. The new target sits near the midpoint of the nine‑analyst consensus range of $20 to $32, and slightly above the current 52‑week high of $21.89. This adjustment suggests the firm sees further upside potential for the company.